Sandoz to build Biosimilar Technical Development Center in Slovenia

Sandoz is to invest approximately USD 90 million at its site in Ljubljana, Slovenia to establish a dedicated Sandoz Biopharma Development Center by 2026.

With this investment, the Ljubljana site will become one of the key locations for biosimilar product development at Sandoz. The new site will lead to the creation of approximately 200 new full-time jobs and further strengthen the company’s capabilities in end-to-end drug substance and drug product development of biosimilars.

The planned investment complements recently announced Sandoz plans to invest at least USD 400 million in a new biologics manufacturing plant in Lendava, Slovenia, as well as expanding its biosimilar development capabilities at its facility in Holzkirchen, Germany. It also builds on existing small molecule product development capabilities in Ljubljana, where Sandoz has successfully established comprehensive capabilities to develop technologically complex generic pharmaceuticals.

Claire D’Abreu Hayling, chief scientific officer, Sandoz, said: “The new Biosimilar Development Center in Ljubljana will build on these capabilities, helping Sandoz to meet rapidly rising global demand for biosimilars and to make an even more meaningful contribution to the long-term viability of healthcare systems around the world.”

Biosimilars play a crucial role in the treatment and prevention of numerous debilitating and life-threatening conditions, including various types of cancer, psoriasis, and arthritis. They drive competition and cost savings, helping to address the escalating cost pressures faced by global healthcare systems.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news